Guard Therapeutics International AB (SE:GUARD)
:GUARD
Want to see SE:GUARD full AI Analyst Report?
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr0.88 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr27.27M
Enterprise Value-kr13.73M
Total Cash (Recent Filing)kr40.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
A1M Platform FocusA platform centered on A1M targets kidney disease biology directly, creating a focused R&D pipeline and potential proprietary therapeutic approaches. This platform orientation can yield durable differentiation, licensing or partnership optionality and scalable program expansion over time.
No Debt On Balance SheetA debt-free capital structure materially reduces mandatory interest and refinancing needs for a clinical-stage biotech. That lowers short-term solvency pressure, giving management more flexibility to time financing around milestones and preserving operating cash for R&D execution.
Cash Aligns With Reported LossesClose alignment between cash outflows and reported losses indicates limited accounting distortions and clearer visibility into true burn. This improves forecasting reliability for runway and financing timelines, aiding durable planning for multi-stage clinical programs.
Bears Say
No Revenue, Large LossesNo commercial revenue and sustained, material net losses mean the business lacks operating cash generation. Long-term viability depends on clinical validation, partnerships, or capital raises; absent those, the company cannot self-fund development or commercialization.
Consistent Heavy Cash BurnRepeated large negative operating cash flows are depleting resources and increase the frequency and size of required financing. For a clinical-stage biotech, this elevates dilution and execution risk, constraining ability to run multiple programs or respond to trial setbacks.
Eroding Equity And AssetsRapid decline in equity and total assets reduces the financial cushion for setbacks and limits bargaining leverage with partners or acquirers. A diminished capital base amplifies downside from trial failures and compresses optionality to scale programs organically.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr0.88 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr27.27M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 13, 2026. The company reported -kr0.315 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.315.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.899%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―